AHSNs in England have supported the rollout of two innovations under the Accelerated Access Collaborative’s Rapid Uptake Products Programme – FeNO, a point of care test to help diagnose asthma, and biologic therapies, NICE-approved treatments for patients with severe asthma which does not respond to regular treatments. Both innovations had lower than expected uptake, presenting an opportunity to improve take-up and support the NHS Long Term Plan ambition of improving early and accurate diagnosis of respiratory conditions by embedding both FeNO testing and asthma biologics into localised clinical pathways.
Led by Oxford AHSN (Asthma Biologics) and Wessex AHSN (FeNO), the project focused on collaboration at a national, regional and local level across healthcare systems, industry partners, patients, and the third sector to support the integration of both FeNO and Asthma Biologics into everyday practice.
AHSNs have worked within their individual systems to support asthma pathway improvements by providing clinical leadership, sharing best practice and developing supporting materials for those involved in asthma care.
A package of educational resources for each innovation, including information documents, podcasts, posters, learning modules and webinars, was created in order to equip clinicians with the tools and knowledge to support clinicians. The toolkits were designed in a practical way to support teams adopting and sustaining the use of FeNO and asthma biologics.
Patient information leaflets, translated into eight different languages, also aimed to empower patients to have informed conversations with their asthma team about their care.